159 related articles for article (PubMed ID: 21496280)
1. Maspin expression is frequent and correlates with basal markers in triple-negative breast cancer.
Umekita Y; Ohi Y; Souda M; Rai Y; Sagara Y; Sagara Y; Tamada S; Tanimoto A
Diagn Pathol; 2011 Apr; 6():36. PubMed ID: 21496280
[TBL] [Abstract][Full Text] [Related]
2. Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.
Nassar A; Sussman ZM; Lawson D; Cohen C
Breast J; 2012 Sep; 18(5):399-405. PubMed ID: 22882580
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers.
Sung H; Garcia-Closas M; Chang-Claude J; Blows FM; Ali HR; Figueroa J; Nevanlinna H; Fagerholm R; Heikkilä P; Blomqvist C; Giles GG; Milne RL; Southey MC; McLean C; Mannermaa A; Kosma VM; Kataja V; Sironen R; Couch FJ; Olson JE; Hallberg E; Olswold C; Cox A; Cross SS; Kraft P; Tamimi RM; Eliassen AH; Schmidt MK; Bolla MK; Wang Q; Easton D; Howat WJ; Coulson P; Pharoah PD; Sherman ME; Yang XR
Br J Cancer; 2016 Feb; 114(3):298-304. PubMed ID: 26679376
[TBL] [Abstract][Full Text] [Related]
4. [Value of CK5/6, CK14, ER and PR detection in differential diagnosis of intraductal proliferative lesions of the breast].
Niu F; Wang L; Zhang W; Lyu S; Niu Y
Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):749-52. PubMed ID: 26813593
[TBL] [Abstract][Full Text] [Related]
5. [Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].
Liu H; Fan QH; Zhang ZH; Li X; Yu HP; Liu GZ; Meng FQ
Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):23-8. PubMed ID: 19489221
[TBL] [Abstract][Full Text] [Related]
6. Basal markers and prognosis in luminal breast cancer.
Engstrøm MJ; Valla M; Bofin AM
Breast Cancer Res Treat; 2017 Jun; 163(2):207-217. PubMed ID: 28258354
[TBL] [Abstract][Full Text] [Related]
7. [Clinicopathologic study of centrally necrotizing carcinoma of breast].
Yu L; Yang WT; Cai X; Lu HF; Fan YZ; Shi DR
Zhonghua Bing Li Xue Za Zhi; 2009 Oct; 38(10):657-62. PubMed ID: 20078968
[TBL] [Abstract][Full Text] [Related]
8. [Expression of CK5/6 and CK17 and its correlation with prognosis of triple-negative breast cancer patients].
Liu ZB; Wu J; Ping B; Feng LQ; Shen ZZ; Shao ZM
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):610-4. PubMed ID: 19102940
[TBL] [Abstract][Full Text] [Related]
9. Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancer.
Guler G; Huebner K; Himmetoglu C; Jimenez RE; Costinean S; Volinia S; Pilarski RT; Hayran M; Shapiro CL
Cancer; 2009 Feb; 115(4):899-908. PubMed ID: 19130459
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic features of breast carcinomas classified by biomarkers and correlation with microvessel density and VEGF expression: a study from Thailand.
Chuangsuwanich T; Pongpruttipan T; O-Charoenrat P; Komoltri C; Watcharahirun S; Sa-Nguanraksa D
Asian Pac J Cancer Prev; 2014; 15(3):1187-92. PubMed ID: 24606439
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic and Functional Characterization of Ductal Carcinoma In Situ-Associated Myoepithelial Cells.
Rohilla M; Bal A; Singh G; Joshi K
Clin Breast Cancer; 2015 Oct; 15(5):335-42. PubMed ID: 25700939
[TBL] [Abstract][Full Text] [Related]
12. Metaplastic breast carcinomas: are they of myoepithelial differentiation?: immunohistochemical profile of the sarcomatoid subtype using novel myoepithelial markers.
Leibl S; Gogg-Kammerer M; Sommersacher A; Denk H; Moinfar F
Am J Surg Pathol; 2005 Mar; 29(3):347-53. PubMed ID: 15725803
[TBL] [Abstract][Full Text] [Related]
13. Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers.
Witkiewicz AK; Dasgupta A; Sammons S; Er O; Potoczek MB; Guiles F; Sotgia F; Brody JR; Mitchell EP; Lisanti MP
Cancer Biol Ther; 2010 Jul; 10(2):135-43. PubMed ID: 20431349
[TBL] [Abstract][Full Text] [Related]
14. [Expression of cytokeratins 5/6 and cytokeratin 17 in invasive breast carcinoma].
Ivković-Kapicl T; Panjković M; Nikolić I; Djilas-Ivanović D; Knezević-Usaj S
Vojnosanit Pregl; 2012 Dec; 69(12):1031-8. PubMed ID: 23424955
[TBL] [Abstract][Full Text] [Related]
15. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
16. Expression of maspin is up-regulated during the progression of mammary ductal carcinoma.
Umekita Y; Yoshida H
Histopathology; 2003 Jun; 42(6):541-5. PubMed ID: 12786889
[TBL] [Abstract][Full Text] [Related]
17. Mammary NOS-type sarcoma with CD10 expression: a rare entity with features of myoepithelial differentiation.
Leibl S; Moinfar F
Am J Surg Pathol; 2006 Apr; 30(4):450-6. PubMed ID: 16625090
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis of ER, PR, HER-2, CK 5/6, p63 and EGFR antigen expression in medullary breast cancer.
Matkovic B; Juretic A; Separovic V; Novosel I; Separovic R; Gamulin M; Kruslin B
Tumori; 2008; 94(6):838-44. PubMed ID: 19267102
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers.
Choi J; Jung WH; Koo JS
Histol Histopathol; 2012 Nov; 27(11):1481-93. PubMed ID: 23018247
[TBL] [Abstract][Full Text] [Related]
20. The unique luminal staining pattern of cytokeratin 5/6 in adenoid cystic carcinoma of the breast may aid in differentiating it from its mimickers.
Nakai T; Ichihara S; Kada A; Ito N; Moritani S; Kawasaki T; Uchiyama T; Itami H; Morita K; Takano M; Takeda M; Hatakeyama K; Ohbayashi C
Virchows Arch; 2016 Aug; 469(2):213-22. PubMed ID: 27240462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]